People

The People

Daqo earns a governance grade in the C+ to B- range: the Xu family has real money on the line and the audit committee is genuinely independent, but a three-generation family board, a CEO who chairs his own nomination committee, a $100M buyback announced and barely executed while insiders were filing Form 144 sales, and a CFO who owns zero stock weigh on trust.

The People Running This Company

Five people decide what happens at Daqo. Three of them share a surname.

The bench is shallow. CEO Xiang Xu has spent his career inside the family conglomerate; he runs 25 of its subsidiaries in addition to DQ. Founder Guangfu Xu (83) still sits on the board and owns more stock than anyone, but stepped back in August 2023 alongside CEO Longgen Zhang's abrupt "personal reasons" exit — a sequence that triggered a Rosen Law class-action probe.

The most notable hire is Ming Yang (CFO since 2015). His resume is the strongest external credential on the team and he is the public face of the IR program. The contradiction: he reportedly owns no Daqo shares after a decade in the role.

The succession story is dynastic. Xiaoyu Xu, the CEO's 30-year-old daughter, joined May 2023 as IR head, became a director that November, and was promoted to Deputy CEO in October 2024 — eighteen months from analyst seat to operational #2, with zero disclosed share ownership.

What They Get Paid

For a company that generated $4.6B of revenue at peak and still carries a ~$1.5B market cap, executive cash compensation is unusually thin — almost all of the value transfer happens through stock.

The signature data point is FY2022: as polysilicon prices peaked and net income hit $1.8B, the company recognized $307M of stock-based compensation — the largest single grant in its history, awarded to insiders at the cyclical top. Since then SBC has remained elevated ($142M, $72M, $56M) even as the company swung to losses. Cumulative grants total 117.7M RSUs and options against 67M ADS outstanding.

Are They Aligned?

The Xu family controls roughly 30% of the company directly through BVI vehicles. That is real skin in the game. The picture gets more complicated when you look at insider behavior since the cycle turned.

Insider trading. As a Cayman-incorporated foreign private issuer, Daqo is exempt from Section 16 / Form 4 filings, so insider trading is only visible through Form 144s (planned sales) and Schedule 13G/A (5%+ holders). Four Form 144s were filed between September and December 2025. There is no equivalent public record of insider buys.

Buyback execution. In August 2025 the board authorized a $100M repurchase program. Six months later management has executed only ~$1M, citing waiting "for clarity on China's anti-involution policies" and the cost of the prospective industry consolidation platform. In Q3 2025 the IR head explained the stock had run from $23 to $31 — "we wanted to purchase more shares, we were waiting." This is the textbook mistake: buy back when expensive, hold cash when cheap. With the stock back near $19 and a ~$1.3B market cap, the program is overdue.

Related-party transactions. Material in form but immaterial in amount. The 20-F discloses ~$0.7M of total annual purchases/services with eleven Daqo Group affiliates. All are controlled by the Xu family conglomerate. In dollars, the leakage is rounding error against a $665M revenue base — but it shows the operating environment is enmeshed with a private family group.

The bigger related-party event is historical: in June 2020 the board sold 4.4% of operating subsidiary Xinjiang Daqo to four insiders (Guangfu Xu, Xiang Xu, Dafeng Shi, then-CEO Longgen Zhang) at a pre-money valuation of RMB 4.52B (~$637M) ahead of the STAR Market listing. When Xinjiang Daqo subsequently IPO'd on the STAR board, those insiders captured a substantial multiple on the pre-IPO discount.

Post-2022 ADS share count has shrunk rather than diluted, with weighted ADS falling from 75.9M to 67.4M. But the buyback pattern is troubling: $486M deployed in 2023 (higher prices) vs $0.9M in 2025 (lower prices). Capital allocation has been procyclical.

Board Quality

On paper the board satisfies NYSE majority-independence: 6 of 11 directors are independent. In practice the room is structurally tilted toward management.

The audit committee is the governance bright spot. Arthur Wong (chair) spent 26 years at Deloitte ending as a Beijing partner, then served as CFO at four China-listed companies. He is the SEC-defined "audit committee financial expert" and is unambiguously independent. Rongling Chen brings ASML / Applied Materials semiconductor expertise. Minsong Liang (PhD Michigan, JD NYU) is an ex-CSRC adviser. The audit committee held four formal meetings in 2025 plus two written resolutions — the highest cadence on the board.

The compensation and nominating committees, by contrast, met by written resolution only once each in 2025. Neither held a formal meeting.

Director tenure and age skew old. Five independent directors are between 61 and 84; three have been on the board since 2009-2011 (16+ year tenure, well past the 10-year mark where independence is typically considered impaired by ISS). Founder Guangfu Xu (83) and independent director Rongling Chen (84) are the same age cohort.

The Verdict

The strongest positives. The Xu family owns ~30% directly — there is no principal-agent problem at the founder level. The audit committee is fully independent and chaired by a Deloitte CPA, which matters for a Chinese ADR where audit risk is the largest tail. CFO Ming Yang has the strongest individual resume on the team and has held the seat for a decade. Cash compensation is modest. Post-2022 buybacks reduced the ADS share count from 75.9M to 67.4M.

The real concerns. Three structural defects matter most. First, the CEO chairs the Nominating & Governance Committee — the body that picks the independent watchdogs — making "independence" partly elective. Second, the Compensation Committee is chaired by a non-independent insider, and the Comp / Nom committees met only by written resolution in 2025, with no formal meetings. Third, succession is dynastic: a 30-year-old daughter promoted from analyst to Deputy CEO in 18 months, with zero disclosed share ownership. Layered on top: a $100M buyback authorized but not executed while the stock sat near multi-year lows and Form 144 sale filings clustered in late 2025; SBC of $307M handed out at the cyclical peak in 2022; and a Cayman / FPI structure that exempts the company from Section 16 / Form 4 transparency.

What would upgrade the grade to B+. Three things together: (a) An independent director — not the CEO — taking the chair of Nominating & Governance. (b) Visible execution of the $100M buyback at current prices, demonstrating the board acts on its own capital allocation signal. (c) A succession plan that names a non-Xu candidate or, at minimum, requires the Deputy CEO to build a meaningful share stake before further promotion.

What would downgrade to D. Any of: (a) a related-party transaction larger than today's rounding-error scale, especially involving Xinjiang Daqo subsidiary stock; (b) auditor turnover or a material weakness in internal controls; (c) a regulatory action by the SEC or PCAOB targeting audit access; (d) acceleration of insider Form 144 selling without offsetting buybacks.